Key statistics
On Friday, Stoke Therapeutics Inc (STOK:NSQ) closed at 36.41, -5.90% below its 52-week high of 38.69, set on Oct 16, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 35.20 |
|---|---|
| High | 36.61 |
| Low | 34.66 |
| Bid | 29.74 |
| Offer | 38.25 |
| Previous close | 35.55 |
| Average volume | 708.74k |
|---|---|
| Shares outstanding | 57.12m |
| Free float | 54.80m |
| P/E (TTM) | 55.17 |
| Market cap | 2.08bn USD |
| EPS (TTM) | 0.66 USD |
Data delayed at least 15 minutes, as of Feb 27 2026 21:15 GMT.
More ▼
- Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
- Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
- Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
More ▼
